Related Experiment Video

Updated: May 7, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

The effect of decreasing statin's dosage on LDL-C levels after target levels achieved

Teng-Yeow Tan1

  • 1Division of Cerebrovascular Disease, Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Acta Neurologica Taiwanica
|September 14, 2013
PubMed

Insights

Reducing statin dosage in stroke patients after achieving target low-density lipoprotein cholesterol (LDL-C) levels leads to higher LDL-C. Maintaining statin dosage is recommended unless contraindications exist to prevent lipid profile deterioration.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Statins are proven to reduce cardio-cerebral vascular events.
  • Lipid-lowering therapy (LLT) is often suboptimal in stroke patients.
  • Statin dosage reduction is common upon achieving target low-density lipoprotein cholesterol (LDL-C) levels.

Purpose of the Study:

  • To investigate lipid profile changes after reducing statin dosage in stroke patients who have achieved target LDL-C levels.
  • To evaluate the clinical implications of statin dosage adjustments in this patient population.

Main Methods:

  • A cohort of 103 stroke patients was followed in an outpatient clinic.
  • Patients were divided into two groups: those whose statin dosage was halved (n=22) and those who maintained their initial dosage (n=81).
  • Lipid profiles were compared before and after LLT adjustment.

Main Results:

  • Patients with reduced statin dosage showed significantly higher follow-up LDL-C levels and a lower percentage of patients achieving LDL-C < 100 mg/dL.
  • Across all patients, follow-up LDL-C levels were higher than baseline, with significant increases in total cholesterol and LDL-C in the reduced-dosage group.
  • No significant changes in high-density lipoprotein cholesterol or triglyceride levels were observed in either group.

Conclusions:

  • Decreasing statin dosage in stroke patients often results in LDL-C levels exceeding 100 mg/dL.
  • Maintaining statin dosage is advisable after target levels are achieved, unless absolute contraindications or adverse effects necessitate adjustment.
  • Further research is needed to understand the clinical impact of lipid profile changes post-LLT adjustment.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
Steady State Concentration01:05

Steady State Concentration

A steady state refers to the level of a drug in the body once it has reached an equilibrium between administration and elimination. It represents the point at which the drug administration rate equals the drug elimination rate, resulting in a relatively constant concentration in the body over time. The dynamic equilibrium is crucial to ensure the drug's effectiveness with minimal risk of toxicity.
Most drugs are administered in repeated doses at fixed intervals or through continuous intravenous...